Product Description
Tretinoin (all-trans-retinoic acid) is a retinol (vitamin A) derivative which has been evaluated as a topical treatment for the symptoms of photodamaged skin. In several well-controlled clinical trials, the proportion of patients showing improvement was significantly higher with 0.01 or 0.05% tretinoin cream than with placebo for criteria such as global assessment, fine and coarse wrinkling, pigmentation and roughness.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7663068/)
Mechanisms of Action: RAR Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bausch Health Americas
Company Location: QUEBEC A8 H7L 4A8
Company CEO: Thomas J. Appio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Germany, Greece, Spain, United Kingdom, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acne Vulgaris
Phase 2: Astrocytoma|Chronic Lymphoid Leukemia|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Leukemia, Plasma Cell|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Multiple Myeloma|Oligodendroglioma|Pancreatic Cancer
Phase 1: Glioma|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20244372 | P1 |
Completed |
Healthy Volunteers |
2025-03-18 |
2025-06-29 |
||
| CTR20211361 | P1 |
Recruiting |
Glioma |
None |
2025-04-29 |
||
| STARPAC2 | P2 |
Active, not recruiting |
Pancreatic Cancer |
2028-06-29 |
2% |
2024-12-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| 2021-003993-30 | P2 |
Active, not recruiting |
Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia|Multiple Myeloma |
2026-10-28 |
|||
| STU-2023-0409 | P2 |
Active, not recruiting |
Colorectal Cancer |
2026-10-01 |
12% |
2025-05-28 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
| UPCC 02322 | P2 |
Recruiting |
Astrocytoma|Oligodendroglioma |
2026-06-01 |
12% |
2022-11-22 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| IDP-121-1 | P2 |
Recruiting |
Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Multiple Myeloma|Chronic Lymphoid Leukemia |
2025-12-31 |
2025-05-02 |
Treatments |
|
| CASSANDRA | P2 |
Recruiting |
Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia|Leukemia, Plasma Cell|Multiple Myeloma|Lymphocytic Chronic B-Cell Leukemia |
2025-12-22 |
12% |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| 23-01/ClindaTret-G | P3 |
Recruiting |
Unknown |
2026-05-06 |
2025-05-02 |
Treatments |
|
| CLITRET/VER | P3 |
Recruiting |
Acne Vulgaris |
2025-12-31 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/08/2025 |
News Article |
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 |
|
06/10/2025 |
News Article |
Sunwing Vacations customers can now book their winter escape to Riu Ventura, an all-new Cancun resort set to open on December 6, 2025 |
|
06/05/2025 |
News Article |
/C O R R E C T I O N -- Thompson Thrift/ |
|
06/05/2025 |
News Article |
Thompson Thrift Hosts Groundbreaking for Final Phase of $750 Million Master-Planned Development Near Indianapolis |